|
시장보고서
상품코드
1907925
야뇨증 시장 : 약제 클래스별, 투여 경로별, 투약형별, 작용 기전별, 처방약 유형별, 연령층별, 성별, 유통 채널별, 최종 사용자별, 지역별Nocturia Market, By Drug Class, By Route of Administration, By Dosage Form, By Mechanism of Action, By Prescription Type, By Age Group, By Gender, By Distribution Channel, By End User, By Geography |
||||||
야뇨증 시장은 2025년에 44억 1,000만 달러로 평가되었고, 2032년까지 76억 1,000만 달러에 이를 것으로 예측됩니다. 2025-2032년 연평균 복합 성장률(CAGR) 8.1%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 44억 1,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 CAGR(2025-2032년) | 8.10% | 예측 금액(2032년) | 76억 1,000만 달러 |
세계의 야뇨증 시장은 보다 광범위한 비뇨기과 및 수면 장애 치료제 시장 상황에서 중요한 부분을 차지하며, 야간에 배뇨를 위해 깨어나는 필요성을 특징으로 하는 일반적인 의료 상태에 대응하고 있습니다. 야뇨증은 세계 수백만 명의 사람들에게 영향을 미치고 있으며, 그 유병률은 연령에 따라 현저하게 증가하여 다양한 인구 통계 그룹에 걸친 남성과 여성 모두에 영향을 미칩니다.
이 증상은 수면 패턴을 방해할 뿐만 아니라 삶의 질(QOL)에 심각한 영향을 미치며 낮에는 피로감, 생산성 저하, 노인의 넘어짐 위험이 증가합니다. 시장에는 데스모프레신, 항콜린제, α차단제 등의 약물 요법을 비롯하여 행동 수정이나 의료기기 등 비약물 요법을 포함한 다양한 치료법이 포함되어 있습니다. 헬스케어 종사자들은 야뇨증를 단순한 기초 질환의 증상이 아닌 표적화된 치료 개입을 필요로 하는 독립적인 질환으로 인식하는 경향이 강해지고 있습니다. 환자 및 헬스케어 전문가가 이용할 수 있는 치료 옵션에 대한 인식이 높아지고, 세계의 고령화, 당뇨병, 심부전 및 전립선 비대증 등 관련 병존 질환의 유병률 상승이 함께, 치료 솔루션 시장 확대와 혁신을 지속적으로 추진하고 있습니다.
시장 역학
세계의 야뇨증 시장은 주로 몇 가지 강력한 요인들에 의해 견인되고 있으며, 이들은 함께 견조한 시장 성장과 확대 기회를 창출하고 있습니다. 가장 중요한 촉진요인은 급속히 노화하는 세계 인구입니다. 야뇨증의 유병률은 노화와 함께 크게 증가하고 65세 이상에서는 최대 80%의 개인에 영향을 미치기 때문에 치료 개입이 필요한 환자 기반이 확대되고 있습니다. 헬스케어 종사자와 환자에서 '야뇨증는 노화에 따른 피할 수 없는 현상이 아니라 치료 가능한 질환이'라는 인식 증가가 진단률 향상 및 치료를 요구하는 행동 증가로 이어지고 있습니다. 또한, 야뇨증의 발병에 기여하는 당뇨병, 심혈관 질환, 양성 전립선 비대증 등 기본 질환의 유병률 증가가 잠재적인 환자층을 더욱 확대하고 있습니다.
그러나 시장에는 현저한 제약도 존재합니다. 환자의 인지 부족에 의한 진단 및 치료의 지연을 들 수 있고, 많은 환자가 노화에 따른 정상적인 현상으로서 받아들여 의료 개입을 요구하지 않는 상황입니다. 특히 야뇨증의 복잡한 병인과 종합적인 안전성 프로파일의 필요성으로 인해 신약 승인의 규제 문제는 혁신적인 치료법 시장 진입을 지연시킬 수 있습니다. 치료비의 고액과 특정 치료법에 대한 보험 적용 범위의 제한은 환자의 최적 치료에 대한 접근을 방해할 수 있습니다. 이러한 과제가 있는 한편, 진단 툴의 기술 진보에 의한 환자층의 보다 정확한 분류나 맞춤형 치료 어프로치의 실현 등, 큰 기회도 존재합니다. 신규 치료 표적 및 병용 요법의 개발은 현저한 성장의 가능성을 나타내고 있으며, 신흥 시장에서의 의료 인프라 확충은 세계의 전개를 목표로 하는 시장 진출 기업에 있어서 새로운 수익원이 될 것입니다.
이 보고서의 주요 특징
- 본 보고서는 세계의 야뇨증 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측 기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
- 또한 각 부문의 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 세계 야뇨증 시장의 주요 기업 프로파일은 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 다음 매개 변수를 기반으로 게시됩니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자 및 기업 경영진은 향후 제품 출시, 제휴, 시장 확대, 마케팅 전술에 대한 충분한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- '세계의 야뇨증 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자는 세계의 야뇨증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적 및 전제조건
- 분석 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의 및 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시 및 승인
- PEST 분석
- Porter's Five Forces 분석
- 기업 합병 및 인수(M&A) 시나리오
- 업계 동향
제4장 세계의 야뇨증 시장 : 약제 클래스별(2020-2032년)
- 항이뇨제(예 : 데스모프레신 등 바소프레신 유사체)
- α-1 아드레날린 수용체 길항제(예 : 탐스로신, 알프조신, 실로도신, 테라조신)
- 항콜린 작용제(예 : 옥시부티닌, 톨테로진, 솔리페나신, 다리페나신, 트로스퓸)
- β3 아드레날린 작용제(예 : 미라베글론, 비베그론)
- 루프 이뇨제의 투여 타이밍 요법(예 : 푸로세미드를 오후 늦게 투여)
- 병용 약물 요법(예 : 미라베그론+소리페나신, α차단제+항콜린제)
제5장 세계의 야뇨증 시장 : 투여 경로별(2020-2032년)
- 경구
- 경비
- 설하 투여 및 구강내 붕괴정
- 비경구, 기타 전신 투여 경로
제6장 세계의 야뇨증 시장 : 제형별(2020-2032년)
- 즉방성 정제 및 캡슐
- 서방형 및 지속성 경구 투여형
- 구강내 붕괴정 및 필름
- 점비약 및 점비액
- 주사제
제7장 세계의 야뇨증 시장 : 작용 기전별(2020-2032년)
- 바소프레신 수용체 작용제
- 평활근 이완약
- 무스카린 수용체 차단제
- β3 수용체 작용제
- 전립선 표적성 이완제
- 체액 조절 모듈레이터
제8장 세계의 야뇨증 시장 : 처방약 유형별(2020-2032년)
- 처방전 의약품(Rx)
- 시판약(OTC)
제9장 세계의 야뇨증 시장 : 연령층별(2020-2032년)
- 성인
- 고령자
제10장 세계의 야뇨증 시장 : 성별(2020-2032년)
- 남성
- 여성
제11장 세계의 야뇨증 시장 : 유통 채널별(2020-2032년)
- 병원 약국
- 소매 약국
- 온라인 약국
제12장 세계의 야뇨증 시장 : 최종 사용자별(2020-2032년)
- 병원
- 전문 비뇨기과 클리닉
- 장기 요양 시설 및 간병 시설
- 재택 치료 및 자기 관리 환경
제13장 세계의 야뇨증 시장 : 지역별(2020-2032년)
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제14장 경쟁 구도
- Ferring Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer Inc.
- AbbVie Inc.
- Merck &Co., Inc.
- Sanofi SA
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Ltd.
- Avadel Pharmaceuticals plc
- Sumitomo Pharma Co., Ltd.
- Urigen Pharmaceuticals Inc.
- Vantia Therapeutics Ltd.
- Viatris Inc.
- Allergan(an AbbVie company)
제15장 애널리스트의 제안
- 기회
- 애널리스트의 견해
- 일관된 기회 지도(COM)
제16장 참고문헌 및 분석 방법
- 참고문헌
- 분석 방법
- Coherent Market Insights에 대해
Nocturia Market is estimated to be valued at USD 4.41 Bn in 2025 and is expected to reach USD 7.61 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.41 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.10% | 2032 Value Projection: | USD 7.61 Bn |
The global nocturia market represents a critical segment within the broader urological and sleep disorder therapeutics landscape, addressing a prevalent medical condition characterized by the need to wake up during the night to urinate. Nocturia affects millions of individuals worldwide, with prevalence rates increasing significantly with age, impacting both men and women across various demographic groups.
This condition not only disrupts sleep patterns but also substantially affects quality of life, leading to daytime fatigue, reduced productivity, and increased risk of falls among elderly populations. The market encompasses various treatment modalities including pharmacological interventions such as desmopressin, anticholinergics, and alpha-blockers, alongside non-pharmacological approaches including behavioral modifications and medical devices. Healthcare providers increasingly recognize nocturia as a distinct medical condition requiring targeted therapeutic intervention rather than merely a symptom of underlying disorders. The growing awareness among patients and healthcare professionals about available treatment options, coupled with an aging global population and rising prevalence of associated comorbidities such as diabetes, heart failure, and benign prostatic hyperplasia, continues to drive market expansion and innovation in therapeutic solutions.
Market Dynamics
The global nocturia market is primarily driven by several compelling factors that collectively contribute to robust market growth and expansion opportunities. The most significant driver is the rapidly aging global population, as nocturia prevalence increases substantially with age, affecting up to 80% of individuals over 65 years, creating an expanding patient base requiring therapeutic intervention. Rising awareness among healthcare providers and patients about nocturia as a treatable medical condition rather than an inevitable aspect of aging has led to increased diagnosis rates and treatment seeking behavior. Additionally, the growing prevalence of underlying conditions such as diabetes mellitus, cardiovascular diseases, and benign prostatic hyperplasia, which contribute to nocturia development, further expands the potential patient population.
However, the market faces notable restraints including limited awareness among patients leading to underdiagnosis and undertreatment, with many individuals accepting the condition as a normal part of aging without seeking medical intervention. Regulatory challenges for new drug approvals, particularly given the complex etiology of nocturia and the need for comprehensive safety profiles, can delay market entry of innovative treatments. High treatment costs and limited insurance coverage for certain therapeutic options may restrict patient access to optimal care. Despite these challenges, significant opportunities exist through technological advancement in diagnostic tools enabling better patient stratification and personalized treatment approaches. The development of novel therapeutic targets and combination therapies presents substantial growth potential, while expanding healthcare infrastructure in emerging markets offers new revenue streams for market participants seeking global expansion.
Key Features of the Study
- This report provides in-depth analysis of the global nocturia market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global nocturia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Ferring Pharmaceuticals, Astellas Pharma Inc., Pfizer Inc., AbbVie Inc., Merck & Co., Inc., Sanofi S.A., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Avadel Pharmaceuticals plc, Sumitomo Pharma Co., Ltd., Urigen Pharmaceuticals Inc., Vantia Therapeutics Ltd., Viatris Inc., Allergan (an AbbVie company).
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global nocturia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nocturia market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
- Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intranasal
- Sublingual/orodispersible
- Parenteral and other systemic routes
- Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Immediate-release tablets or capsules
- Modified/extended-release oral formulations
- Orodispersible tablets or film
- Nasal sprays or drops
- Injectable formulations
- Mechanism Of Action Insights (Revenue, USD Bn, 2020 - 2032)
- Vasopressin Receptor Agonists
- Smooth Muscle Relaxants
- Muscarinic Receptor Blockers
- Beta-3 Receptor Stimulants
- Prostate-Targeted Relaxants
- Fluid-Regulation Modulators
- Prescription Type Insights (Revenue, USD Bn, 2020 - 2032)
- Prescription-Only Medicines (Rx)
- Over-the-Counter Options (OTC)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty urology clinics
- Long-term care and nursing facilities
- Home-care and self-administration settings
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Ferring Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Sanofi S.A.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Ltd.
- Avadel Pharmaceuticals plc
- Sumitomo Pharma Co., Ltd.
- Urigen Pharmaceuticals Inc.
- Vantia Therapeutics Ltd.
- Viatris Inc.
- Allergan (an AbbVie company)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Nocturia Market, By Drug Class
- Global Nocturia Market, By Route of Administration
- Global Nocturia Market, By Dosage Form
- Global Nocturia Market, By Mechanism of Action
- Global Nocturia Market, By Prescription Type
- Global Nocturia Market, By Age Group
- Global Nocturia Market, By Gender
- Global Nocturia Market, By Distribution Channel
- Global Nocturia Market, By End User
- Global Nocturia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Nocturia Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Nocturia Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sublingual/orodispersible
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral and other systemic routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Nocturia Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immediate-release tablets or capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Modified/extended-release oral formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Orodispersible tablets or film
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Nasal sprays or drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Nocturia Market, By Mechanism of Action, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Vasopressin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Smooth Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Muscarinic Receptor Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Beta-3 Receptor Stimulants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prostate-Targeted Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Fluid-Regulation Modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Nocturia Market, By Prescription Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Prescription-Only Medicines (Rx)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Over-the-Counter Options (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Nocturia Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Nocturia Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Nocturia Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Nocturia Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty urology clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-term care and nursing facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home-care and self-administration settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global Nocturia Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Ferring Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Avadel Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Urigen Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vantia Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan (an AbbVie company)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
